Biogen Raises Guidance as It Looks to the Pipeline for Growth
Biogen (NASDAQ: BIIB) put up relatively impressive sales numbers in the second quarter, with earnings per share growing like gangbusters as the drugmaker cut expenses and repurchased shares to boost the bottom line.
Metric
Q2 2019
Quelle Fool.com